<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02634983</url>
  </required_header>
  <id_info>
    <org_study_id>CQVA149A2325</org_study_id>
    <secondary_id>2013-004461-13</secondary_id>
    <nct_id>NCT02634983</nct_id>
  </id_info>
  <brief_title>QVA Mechanistic Efficacy Study (Receptor Effects, Etc)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Two-period Crossover Study to Assess the Effect of Inhaled QVA149 on Global and Regional Lung Function and Gas Exchange in Patients With Moderate to Severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess global ventilated lung volume in moderate to severe
      COPD patients using MRI lung imaging after treatment with QVA149 compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MRI approach represented an opportunity to better understand the impact of a potent dual
      bronchodilator on the small and central airways and thereby increasing ventilated lung
      volume, gas exchange, and ventilation-perfusion deficits.

      The study investigated the effect of QVA149 on global and regional lung ventilation using MRI
      lung imaging to enhance the understanding of QVA pharmacology in COPD patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 3, 2016</start_date>
  <completion_date type="Actual">September 26, 2017</completion_date>
  <primary_completion_date type="Actual">September 26, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Ventilated Lung Volume</measure>
    <time_frame>Day 8 to Day 10 (each treatment period)</time_frame>
    <description>The global distribution of inhaled gas within the lung was assessed using an inhaled gaseous contrast agent, Hyperpolarized Helium (3He) Lung Imaging. The Global Ventilated Lung Volume was expressed in percentage (%VV) of total lung volume.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional Ventilated Lung Volume</measure>
    <time_frame>Day 8 to Day 10 (each treatment period)</time_frame>
    <description>The regional distribution of inhaled gas within the lung was assessed using an inhaled gaseous contrast agent, Hyperpolarized Helium (3He) Lung Imaging. The Regional Ventilated Lung Volume was expressed in percentage (% VDV) of total lung volume for each lobar region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Perfusion</measure>
    <time_frame>Day 8 to Day 10 (each treatment period)</time_frame>
    <description>Lung Perfusion Imaging, or MR perfusion imaging of the lung with gadolinium contrast agent, was performed to determine whether vascular abnormalities producing perfusion deficits corresponded to abnormalities in ventilation (hypoxic vasoconstriction). Pulmonary Perfusion was expressed in ml/100 g lung tissue/min of each lobar region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 1 (0.25, 1 and 2 hours post-dose), Day 8 (-0.75, -0.25, 0.25, 1 and 2 hours post-dose) (each treatment period)</time_frame>
    <description>The Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>Day 1 (0.25, 1 and 2 hours post-dose), Day 8 (-0.75, -0.25, 0.25, 1 and 2 hours post-dose) (each treatment period)</time_frame>
    <description>Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. An increase in FVC indicates improvement in lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC Ratio</measure>
    <time_frame>Day 1 (0.25, 1 and 2 hours post-dose), Day 8 (-0.75, -0.25, 0.25, 1 and 2 hours post-dose) (each treatment period)</time_frame>
    <description>The FEV1/FVC ratio is the proportion of a person's vital capacity that they are able to expire in the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC). The result of this ratio is expressed as FEV1%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Clearance Index by Multiple Breath Nitrogen Washout (MBNW)</measure>
    <time_frame>Day 8 (each treatment period)</time_frame>
    <description>Multiple Breath Nitrogen Washout (MBNW) was performed after 2 hours post-dose spirometry assessments using a multiple breath inert gas washout technique. The device provides the global index of ventilation inhomogeneity assessment (LCI = Cumulative Expired Volume/Functional Residual Capacity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)</measure>
    <time_frame>Day 8 (each treatment period)</time_frame>
    <description>The diffusing capacity of the lung for carbon monoxide (DLCO) is a measure of how easily carbon monoxide (CO) molecules transfer from the alveolar gas to the hemoglobin of the red cells in the pulmonary circulation. To measure the DLCO, the patient inhales a single breath containing a minute amount of CO and holds it for 10 seconds. The breath is then exhaled and the exhaled breath is analyzed for CO. The change in the concentration of the CO is then multiplied by the single breath TLC to calculate the DLCO.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>QVA149 110/50 mcg then Matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single daily dose of 110/50 μg QVA149 for 8-10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo then QVA149 110/50 mcg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single daily dose of matching placebo for 8-10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QVA149</intervention_name>
    <description>QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.</description>
    <arm_group_label>Matching placebo then QVA149 110/50 mcg</arm_group_label>
    <arm_group_label>QVA149 110/50 mcg then Matching placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Matching placebo then QVA149 110/50 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        Males and females with COPD aged 40 years and above, weighing ≥45 kg and ≤100 kg, who were
        smokers and ex-smokers who had a smoking history of at least 10 pack years, and diagnosed
        with moderate to severe COPD according to GOLD 2015 criteria were included in the study.
        Patients with airflow limitation indicated by a post-bronchodilator FEV1/FVC &lt; 0.70 and by
        a post-bronchodilator FEV1 ≥ 30 % and &lt;80 % were included in the study. Post-bronchodilator
        refers to 1 hr (+/- 5 minutes) after sequential inhalation of 84 µg ipratropium bromide (or
        equivalent dose) and 400 µg salbutamol/360 µg albuterol (or equivalent dose).

        Key Exclusion Criteria:

        Patients with conditions which could compromise patient safety and compliance (as judged by
        the investigator), as well as conditions that required oxygen therapy for chronic
        hypoxemia, ≥25% emphysematous changes on a scan within 6 months to screening, those with
        lower respiratory infections within 6 weeks of screening, and patients with concomitant
        pulmonary disease were excluded from the study. Patients with asthma were also excluded
        from the study.

        Pregnant or nursing (lactating) women, patients with poorly controlled Type I or Type II
        diabetes, patients with poor renal function, and those who were unable to use a dry powder
        inhaler or perform spirometry, and had contraindications to MRI were also excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bradford</city>
        <state>West Yorkshire</state>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 28, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2015</study_first_posted>
  <results_first_submitted>September 25, 2018</results_first_submitted>
  <results_first_submitted_qc>February 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 3, 2019</results_first_posted>
  <last_update_submitted>February 22, 2019</last_update_submitted>
  <last_update_submitted_qc>February 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Smokers</keyword>
  <keyword>Ex-smokers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02634983/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 13, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02634983/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study took place in 3 clinical sites in United-Kingdom</recruitment_details>
      <pre_assignment_details>31 patients were randomized, all of whom were included in the safety set and PD analysis sets (primary population of interest)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>QVA149 110/50 mcg Then Matching Placebo</title>
          <description>QVA149, followed by matching placebo. Each treatment 8-10 days.</description>
        </group>
        <group group_id="P2">
          <title>Matching Placebo Then QVA149 110/50 mcg</title>
          <description>Matching placebo, followed by QVA149. Each treatment 8-10 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period One (First Treatment, 8-10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (Approximately 7-14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2 (Second Treatment, 8-10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants who were randomized to receive either QVA149 110/50 mcg or Placebo matching QVA149 110/50 mcg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.9" spread="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced Expiratory Volume in 1 Second</title>
          <description>Spirometry assessments are to be performed 60 minutes post short-acting β2-adrenergic agonist (SABA) and short-acting muscarinic antagonist (SAMA) inhalation as part of the Baseline assessments. The Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.</description>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>0 Minutes Pre Inhalation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1584" spread="0.35206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Minutes Post Inhalation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3987" spread="0.37266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent Predicted FEV1</title>
          <description>Spirometry assessments are to be performed 60 minutes post short-acting β2-adrenergic agonist (SABA) and short-acting muscarinic antagonist (SAMA) inhalation as part of the Baseline assessments.</description>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>0 Minutes Pre Inhalation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.90" spread="10.873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Minutes Post Inhalation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.10" spread="11.680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced Vital Capacity</title>
          <description>Spirometry assessments are to be performed 60 minutes post short-acting β2-adrenergic agonist (SABA) and short-acting muscarinic antagonist (SAMA) inhalation as part of the Baseline assessments. Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry.</description>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>0 Minutes Pre Inhalation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7426" spread="0.73932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Minutes Post Inhalation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.0781" spread="0.81113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1/FVC ratio</title>
          <description>Spirometry assessments are to be performed 60 minutes post short-acting β2-adrenergic agonist (SABA) and short-acting muscarinic antagonist (SAMA) inhalation as part of the Baseline assessments. The FEV1/FVC ratio is the proportion of a person's vital capacity that they are able to expire in the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC).</description>
          <units>Percent ((FEV1/FVC)*100)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>0 Minutes Pre Inhalation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.968" spread="8.9797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Minutes Post Inhalation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.365" spread="8.8240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reversibility</title>
          <description>Reversibility = FEV1 post-inhalation - FEV1 pre-inhalation. Reversibility was reported in absolute FEV1 values pre- and post-bronchodilator.</description>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.2403" spread="0.12994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reversibility</title>
          <description>Reversibility = FEV1 post-inhalation - FEV1 pre-inhalation. Reversibility was reported in change in FEV1 between pre- and postbronchodilator assessment expressed in % of pre-bronchodilator FEV1.</description>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.19" spread="4.743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Global Ventilated Lung Volume</title>
        <description>The global distribution of inhaled gas within the lung was assessed using an inhaled gaseous contrast agent, Hyperpolarized Helium (3He) Lung Imaging. The Global Ventilated Lung Volume was expressed in percentage (%VV) of total lung volume.</description>
        <time_frame>Day 8 to Day 10 (each treatment period)</time_frame>
        <population>The PD Analysis Set, which consisted of all participants with valid results assessed in each treatment period, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149 110/50 mcg</title>
            <description>Single daily dose of 110/50 μg QVA149 for 8-10 days.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Single daily dose of matching placebo for 8-10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Ventilated Lung Volume</title>
          <description>The global distribution of inhaled gas within the lung was assessed using an inhaled gaseous contrast agent, Hyperpolarized Helium (3He) Lung Imaging. The Global Ventilated Lung Volume was expressed in percentage (%VV) of total lung volume.</description>
          <population>The PD Analysis Set, which consisted of all participants with valid results assessed in each treatment period, was considered.</population>
          <units>Percentage of total lung volume</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.73" lower_limit="56.16" upper_limit="67.30"/>
                    <measurement group_id="O2" value="56.73" lower_limit="51.07" upper_limit="62.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Global Ventilated Lung Volume</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.0254</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.11</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.40</ci_lower_limit>
            <ci_upper_limit>8.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Regional Ventilated Lung Volume</title>
        <description>The regional distribution of inhaled gas within the lung was assessed using an inhaled gaseous contrast agent, Hyperpolarized Helium (3He) Lung Imaging. The Regional Ventilated Lung Volume was expressed in percentage (% VDV) of total lung volume for each lobar region.</description>
        <time_frame>Day 8 to Day 10 (each treatment period)</time_frame>
        <population>The PD Analysis Set, which consisted of all participants with valid results assessed in each treatment period, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149 110/50 mcg</title>
            <description>Single daily dose of 110/50 μg QVA149 for 8-10 days.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Single daily dose of matching placebo for 8-10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Regional Ventilated Lung Volume</title>
          <description>The regional distribution of inhaled gas within the lung was assessed using an inhaled gaseous contrast agent, Hyperpolarized Helium (3He) Lung Imaging. The Regional Ventilated Lung Volume was expressed in percentage (% VDV) of total lung volume for each lobar region.</description>
          <population>The PD Analysis Set, which consisted of all participants with valid results assessed in each treatment period, was considered.</population>
          <units>Percentage of total lung volume</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lung, Left Ventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.94" lower_limit="56.04" upper_limit="67.83"/>
                    <measurement group_id="O2" value="57.16" lower_limit="51.17" upper_limit="63.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung, Left Lower Lobe Ventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.97" lower_limit="52.63" upper_limit="65.31"/>
                    <measurement group_id="O2" value="54.01" lower_limit="47.52" upper_limit="60.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung, Left Upper Lobe Ventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.17" lower_limit="57.95" upper_limit="70.39"/>
                    <measurement group_id="O2" value="59.20" lower_limit="52.87" upper_limit="65.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung, Right Ventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.63" lower_limit="55.90" upper_limit="67.36"/>
                    <measurement group_id="O2" value="56.24" lower_limit="50.40" upper_limit="62.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung, Right Lower Lobe Ventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.92" lower_limit="54.62" upper_limit="67.21"/>
                    <measurement group_id="O2" value="57.65" lower_limit="51.26" upper_limit="64.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung, Right Middle Lobe Ventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.59" lower_limit="52.85" upper_limit="66.34"/>
                    <measurement group_id="O2" value="53.98" lower_limit="47.01" upper_limit="60.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung, Right Upper Lobe Ventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.25" lower_limit="56.71" upper_limit="69.79"/>
                    <measurement group_id="O2" value="55.53" lower_limit="48.85" upper_limit="62.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lung, Left Ventilation</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.0350</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.15</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>8.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lung, Left Lower Lobe Ventilation</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.0946</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.86</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>9.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lung, Left Upper Lobe Ventilation</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.0486</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.41</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>9.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lung, Right Ventilation</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.0286</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.33</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.42</ci_lower_limit>
            <ci_upper_limit>9.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lung, Right Lower Lobe Ventilation</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.1650</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.29</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>7.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lung, Right Middle Lobe Ventilation</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.1421</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.71</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>11.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lung, Right Upper Lobe Ventilation</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.0099</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.78</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.98</ci_lower_limit>
            <ci_upper_limit>12.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Perfusion</title>
        <description>Lung Perfusion Imaging, or MR perfusion imaging of the lung with gadolinium contrast agent, was performed to determine whether vascular abnormalities producing perfusion deficits corresponded to abnormalities in ventilation (hypoxic vasoconstriction). Pulmonary Perfusion was expressed in ml/100 g lung tissue/min of each lobar region.</description>
        <time_frame>Day 8 to Day 10 (each treatment period)</time_frame>
        <population>The PD Analysis Set, which consisted of all participants with valid results assessed in each treatment period, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149 110/50 mcg</title>
            <description>Single daily dose of 110/50 μg QVA149 for 8-10 days.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Single daily dose of matching placebo for 8-10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Perfusion</title>
          <description>Lung Perfusion Imaging, or MR perfusion imaging of the lung with gadolinium contrast agent, was performed to determine whether vascular abnormalities producing perfusion deficits corresponded to abnormalities in ventilation (hypoxic vasoconstriction). Pulmonary Perfusion was expressed in ml/100 g lung tissue/min of each lobar region.</description>
          <population>The PD Analysis Set, which consisted of all participants with valid results assessed in each treatment period, was considered.</population>
          <units>ml/100 g lung tissue/min</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lung Perfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.96" lower_limit="12.50" upper_limit="15.41"/>
                    <measurement group_id="O2" value="13.03" lower_limit="11.56" upper_limit="14.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung, Left Perfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.42" lower_limit="12.94" upper_limit="15.90"/>
                    <measurement group_id="O2" value="13.08" lower_limit="11.58" upper_limit="14.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung, Left Lower Lobe Perfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.48" lower_limit="11.91" upper_limit="15.06"/>
                    <measurement group_id="O2" value="12.79" lower_limit="11.20" upper_limit="14.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung, Left Upper Lobe Perfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.35" lower_limit="13.69" upper_limit="17.01"/>
                    <measurement group_id="O2" value="13.45" lower_limit="11.77" upper_limit="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung, Right Perfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.54" lower_limit="12.07" upper_limit="15.01"/>
                    <measurement group_id="O2" value="12.97" lower_limit="11.49" upper_limit="14.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung, Right Lower Lobe Perfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.26" lower_limit="11.74" upper_limit="14.79"/>
                    <measurement group_id="O2" value="13.25" lower_limit="11.71" upper_limit="14.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung, Right Middle Lobe Perfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.86" lower_limit="12.72" upper_limit="17.00"/>
                    <measurement group_id="O2" value="13.36" lower_limit="11.19" upper_limit="15.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung, Right Upper Lobe Perfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.57" lower_limit="11.91" upper_limit="15.23"/>
                    <measurement group_id="O2" value="12.70" lower_limit="11.03" upper_limit="14.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lung Perfusion</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.3230</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.92</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>2.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lung, Left Perfusion</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.1717</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.95</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.29</ci_lower_limit>
            <ci_upper_limit>2.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lung, Left Lower Lobe Perfusion</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.5031</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.02</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lung, Left Upper Lobe Perfusion</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.0760</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.03</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>3.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lung, Right Perfusion</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.5465</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.93</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.02</ci_lower_limit>
            <ci_upper_limit>2.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lung, Right Lower Lobe Perfusion</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.9913</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.08</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.85</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lung, Right Middle Lobe Perfusion</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.3837</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.70</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>4.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lung, Right Upper Lobe Perfusion</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.3624</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.94</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>2.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>The Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.</description>
        <time_frame>Day 1 (0.25, 1 and 2 hours post-dose), Day 8 (-0.75, -0.25, 0.25, 1 and 2 hours post-dose) (each treatment period)</time_frame>
        <population>The PD Analysis Set, which consisted of all participants with valid results assessed in each treatment period, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149 110/50 mcg</title>
            <description>Single daily dose of 110/50 μg QVA149 for 8-10 days.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Single daily dose of matching placebo for 8-10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>The Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.</description>
          <population>The PD Analysis Set, which consisted of all participants with valid results assessed in each treatment period, was considered.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FEV1 Day 1 (0.25 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" lower_limit="1.25" upper_limit="1.30"/>
                    <measurement group_id="O2" value="1.13" lower_limit="1.10" upper_limit="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1 Day 1 (1 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="1.29" upper_limit="1.36"/>
                    <measurement group_id="O2" value="1.12" lower_limit="1.09" upper_limit="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1 Day 1 (2 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" lower_limit="1.30" upper_limit="1.38"/>
                    <measurement group_id="O2" value="1.15" lower_limit="1.11" upper_limit="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1 Day 8 (-0.75 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" lower_limit="1.26" upper_limit="1.34"/>
                    <measurement group_id="O2" value="1.09" lower_limit="1.05" upper_limit="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1 Day 8 (-0.25 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="1.29" upper_limit="1.37"/>
                    <measurement group_id="O2" value="1.11" lower_limit="1.07" upper_limit="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1 Day 8 (0.25 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" lower_limit="1.35" upper_limit="1.42"/>
                    <measurement group_id="O2" value="1.10" lower_limit="1.06" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1 Day 8 (1 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" lower_limit="1.41" upper_limit="1.49"/>
                    <measurement group_id="O2" value="1.13" lower_limit="1.09" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1 Day 8 (2 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" lower_limit="1.39" upper_limit="1.47"/>
                    <measurement group_id="O2" value="1.11" lower_limit="1.07" upper_limit="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEV1 Day 1 (0.25 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEV1 Day 1 (1 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEV1 Day 1 (2 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEV1 Day 8 (-0.75 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEV1 Day 8 (-0.25 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEV1 Day 8 (0.25 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEV1 Day 8 (1 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEV1 Day 8 (2 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC)</title>
        <description>Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. An increase in FVC indicates improvement in lung function.</description>
        <time_frame>Day 1 (0.25, 1 and 2 hours post-dose), Day 8 (-0.75, -0.25, 0.25, 1 and 2 hours post-dose) (each treatment period)</time_frame>
        <population>The PD Analysis Set, which consisted of all participants with valid results assessed in each treatment period, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149 110/50 mcg</title>
            <description>Single daily dose of 110/50 μg QVA149 for 8-10 days.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Single daily dose of matching placebo for 8-10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC)</title>
          <description>Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. An increase in FVC indicates improvement in lung function.</description>
          <population>The PD Analysis Set, which consisted of all participants with valid results assessed in each treatment period, was considered.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FVC Day 1 (0.25 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" lower_limit="2.85" upper_limit="2.98"/>
                    <measurement group_id="O2" value="2.68" lower_limit="2.61" upper_limit="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC Day 1 (1 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" lower_limit="2.91" upper_limit="3.06"/>
                    <measurement group_id="O2" value="2.63" lower_limit="2.56" upper_limit="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC Day 1 (2 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" lower_limit="2.91" upper_limit="3.07"/>
                    <measurement group_id="O2" value="2.68" lower_limit="2.59" upper_limit="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC Day 8 (-0.75 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" lower_limit="2.84" upper_limit="2.98"/>
                    <measurement group_id="O2" value="2.56" lower_limit="2.49" upper_limit="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC Day 8 (-0.25 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" lower_limit="2.84" upper_limit="2.98"/>
                    <measurement group_id="O2" value="2.63" lower_limit="2.56" upper_limit="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC Day 8 (0.25 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" lower_limit="2.95" upper_limit="3.09"/>
                    <measurement group_id="O2" value="2.59" lower_limit="2.51" upper_limit="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC Day 8 (1 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" lower_limit="3.04" upper_limit="3.17"/>
                    <measurement group_id="O2" value="2.65" lower_limit="2.58" upper_limit="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC Day 8 (2 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" lower_limit="2.98" upper_limit="3.13"/>
                    <measurement group_id="O2" value="2.62" lower_limit="2.54" upper_limit="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FVC Day 1 (0.25 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FVC Day 1 (1 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FVC Day 1 (2 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FVC Day 8 (-0.75 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FVC Day 8 (-0.25 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FVC Day 8 (0.25 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FVC Day 8 (1 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FVC Day 8 (2 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1/FVC Ratio</title>
        <description>The FEV1/FVC ratio is the proportion of a person's vital capacity that they are able to expire in the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC). The result of this ratio is expressed as FEV1%.</description>
        <time_frame>Day 1 (0.25, 1 and 2 hours post-dose), Day 8 (-0.75, -0.25, 0.25, 1 and 2 hours post-dose) (each treatment period)</time_frame>
        <population>The PD Analysis Set, which consisted of all participants with valid results assessed in each treatment period, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149 110/50 mcg</title>
            <description>Single daily dose of 110/50 μg QVA149 for 8-10 days.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Single daily dose of matching placebo for 8-10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1/FVC Ratio</title>
          <description>The FEV1/FVC ratio is the proportion of a person's vital capacity that they are able to expire in the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC). The result of this ratio is expressed as FEV1%.</description>
          <population>The PD Analysis Set, which consisted of all participants with valid results assessed in each treatment period, was considered.</population>
          <units>FEV1 Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FEV1/FVC Day 1 (0.25 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.31" lower_limit="43.59" upper_limit="45.02"/>
                    <measurement group_id="O2" value="42.14" lower_limit="41.39" upper_limit="42.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1/FVC Day 1 (1 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.97" lower_limit="44.05" upper_limit="45.88"/>
                    <measurement group_id="O2" value="42.91" lower_limit="41.95" upper_limit="43.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1/FVC Day 1 (2 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.25" lower_limit="44.42" upper_limit="46.08"/>
                    <measurement group_id="O2" value="42.93" lower_limit="42.08" upper_limit="43.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1/FVC Day 8 (-0.75 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.05" lower_limit="44.05" upper_limit="46.05"/>
                    <measurement group_id="O2" value="42.23" lower_limit="41.16" upper_limit="43.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1/FVC Day 8 (-0.25 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.97" lower_limit="45.05" upper_limit="46.89"/>
                    <measurement group_id="O2" value="42.17" lower_limit="41.19" upper_limit="43.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1/FVC Day 8 (0.25 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.34" lower_limit="45.43" upper_limit="47.26"/>
                    <measurement group_id="O2" value="42.60" lower_limit="41.63" upper_limit="43.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1/FVC Day 8 (1 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.32" lower_limit="46.31" upper_limit="48.33"/>
                    <measurement group_id="O2" value="42.72" lower_limit="41.64" upper_limit="43.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1/FVC Day 8 (2 hrs post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.39" lower_limit="46.39" upper_limit="48.40"/>
                    <measurement group_id="O2" value="42.42" lower_limit="41.35" upper_limit="43.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEV1/FVC Day 1 (0.25 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>0.0006</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.56</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>3.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEV1/FVC Day 1 (1 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>0.0106</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.75</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>3.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEV1/FVC Day 1 (2 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>0.0013</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.66</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.20</ci_lower_limit>
            <ci_upper_limit>3.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEV1/FVC Day 8 (-0.75 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>0.0017</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.83</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.41</ci_lower_limit>
            <ci_upper_limit>4.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEV1/FVC Day 8 (-0.25 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.51</ci_lower_limit>
            <ci_upper_limit>5.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEV1/FVC Day 8 (0.25 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.75</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.45</ci_lower_limit>
            <ci_upper_limit>5.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEV1/FVC Day 8 (1 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.85</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.16</ci_lower_limit>
            <ci_upper_limit>6.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEV1/FVC Day 8 (2 hrs post-dose)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment, time and treatment*Day*time interaction term as fixed factors and patient factor as random factor. Day*time was repeated within each patient*period interaction and subject average baseline and period adjusted baseline were included as covariates.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.83</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.56</ci_lower_limit>
            <ci_upper_limit>6.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Clearance Index by Multiple Breath Nitrogen Washout (MBNW)</title>
        <description>Multiple Breath Nitrogen Washout (MBNW) was performed after 2 hours post-dose spirometry assessments using a multiple breath inert gas washout technique. The device provides the global index of ventilation inhomogeneity assessment (LCI = Cumulative Expired Volume/Functional Residual Capacity).</description>
        <time_frame>Day 8 (each treatment period)</time_frame>
        <population>The PD Analysis Set, which consisted of all participants with valid results assessed in each treatment period, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149 110/50 mcg</title>
            <description>Single daily dose of 110/50 μg QVA149 for 8-10 days.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Single daily dose of matching placebo for 8-10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Clearance Index by Multiple Breath Nitrogen Washout (MBNW)</title>
          <description>Multiple Breath Nitrogen Washout (MBNW) was performed after 2 hours post-dose spirometry assessments using a multiple breath inert gas washout technique. The device provides the global index of ventilation inhomogeneity assessment (LCI = Cumulative Expired Volume/Functional Residual Capacity).</description>
          <population>The PD Analysis Set, which consisted of all participants with valid results assessed in each treatment period, was considered.</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.80" lower_limit="10.22" upper_limit="11.37"/>
                    <measurement group_id="O2" value="10.81" lower_limit="10.20" upper_limit="11.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lung Clearance Index</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.9820</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)</title>
        <description>The diffusing capacity of the lung for carbon monoxide (DLCO) is a measure of how easily carbon monoxide (CO) molecules transfer from the alveolar gas to the hemoglobin of the red cells in the pulmonary circulation. To measure the DLCO, the patient inhales a single breath containing a minute amount of CO and holds it for 10 seconds. The breath is then exhaled and the exhaled breath is analyzed for CO. The change in the concentration of the CO is then multiplied by the single breath TLC to calculate the DLCO.</description>
        <time_frame>Day 8 (each treatment period)</time_frame>
        <population>The PD Analysis Set, which consisted of all participants with valid results assessed in each treatment period, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149 110/50 mcg</title>
            <description>Single daily dose of 110/50 μg QVA149 for 8-10 days.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Single daily dose of matching placebo for 8-10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)</title>
          <description>The diffusing capacity of the lung for carbon monoxide (DLCO) is a measure of how easily carbon monoxide (CO) molecules transfer from the alveolar gas to the hemoglobin of the red cells in the pulmonary circulation. To measure the DLCO, the patient inhales a single breath containing a minute amount of CO and holds it for 10 seconds. The breath is then exhaled and the exhaled breath is analyzed for CO. The change in the concentration of the CO is then multiplied by the single breath TLC to calculate the DLCO.</description>
          <population>The PD Analysis Set, which consisted of all participants with valid results assessed in each treatment period, was considered.</population>
          <units>mL/min/mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.38" lower_limit="14.77" upper_limit="18.00"/>
                    <measurement group_id="O2" value="15.73" lower_limit="14.10" upper_limit="17.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diffusion Capacity of Lung for CO</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Parameters were analyzed using mixed effects model including sequence, period, treatment as fixed factors and patient as random factor.</non_inferiority_desc>
            <p_value>0.0821</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 1 year.</time_frame>
      <desc>Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events fields &quot;number of deaths resulting from adverse events&quot; all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.</desc>
      <group_list>
        <group group_id="E1">
          <title>QVA149 110/50 mcg</title>
          <description>Single daily dose of 110/50 μg QVA149 for 8-10 days.</description>
        </group>
        <group group_id="E2">
          <title>Matching Placebo</title>
          <description>Single daily dose of matching placebo for 8-10 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

